Regeneron earns mid-stage win for higher dose of Eylea, hoping to refresh its sales pitch
Regeneron has made its name on the blockbuster success of eye drug Eylea, but with the aging drug facing a raft of competitors the drugmaker …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
